Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

An ultrasensitive test for profiling circulating tumor DNA using integrated comprehensive droplet digital detection.

Ou CY, Vu T, Grunwald JT, Toledano M, Zimak J, Toosky M, Shen B, Zell JA, Gratton E, Abram TJ, Zhao W.

Lab Chip. 2019 Mar 13;19(6):993-1005. doi: 10.1039/c8lc01399c.

PMID:
30735225
2.

The impact of gender, race, socioeconomic status, and treatment on outcomes in esophageal cancer: A population-based analysis.

Tran PN, Taylor TH, Klempner SJ, Zell JA.

J Carcinog. 2017 Sep 18;16:3. doi: 10.4103/jcar.JCar_4_17. eCollection 2017.

3.

Trends in colorectal cancer admissions and stage at presentation: impact of screening.

Moghadamyeghaneh Z, Alizadeh RF, Phelan M, Carmichael JC, Mills S, Pigazzi A, Zell JA, Stamos MJ.

Surg Endosc. 2016 Aug;30(8):3604-10. doi: 10.1007/s00464-015-4662-3. Epub 2015 Nov 5.

4.

Digital quantification of miRNA directly in plasma using integrated comprehensive droplet digital detection.

Zhang K, Kang DK, Ali MM, Liu L, Labanieh L, Lu M, Riazifar H, Nguyen TN, Zell JA, Digman MA, Gratton E, Li J, Zhao W.

Lab Chip. 2015 Nov 7;15(21):4217-26. doi: 10.1039/c5lc00650c. Epub 2015 Sep 21.

5.

A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum.

Gillen DL, Meyskens FL, Morgan TR, Zell JA, Carroll R, Benya R, Chen WP, Mo A, Tucker C, Bhattacharya A, Huang Z, Arcilla M, Wong V, Chung J, Gonzalez R, Rodriguez LM, Szabo E, Rosenberg DW, Lipkin SM.

Cancer Prev Res (Phila). 2015 Mar;8(3):222-30. doi: 10.1158/1940-6207.CAPR-14-0148. Epub 2015 Jan 20.

6.

Colorectal Cancer Incidence Among Young Adults in California.

Singh KE, Taylor TH, Pan CG, Stamos MJ, Zell JA.

J Adolesc Young Adult Oncol. 2014 Dec 1;3(4):176-184.

7.

Role of primary tumor resection among chemotherapy-treated patients with synchronous stage IV colorectal cancer: a survival analysis.

Tsang WY, Ziogas A, Lin BS, Seery TE, Karnes W, Stamos MJ, Zell JA.

J Gastrointest Surg. 2014 Mar;18(3):592-8. doi: 10.1007/s11605-013-2421-0. Epub 2013 Dec 3.

8.

Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas.

Raj KP, Zell JA, Rock CL, McLaren CE, Zoumas-Morse C, Gerner EW, Meyskens FL.

Br J Cancer. 2013 Feb 19;108(3):512-8. doi: 10.1038/bjc.2013.15. Epub 2013 Jan 22.

9.

Everolimus causing severe hypertriglyceridemia and acute pancreatitis.

Subramaniam S, Zell JA, Kunz PL.

J Natl Compr Canc Netw. 2013 Jan 1;11(1):5-9.

PMID:
23307976
10.

Mortality risk after preoperative versus postoperative chemotherapy and radiotherapy in lymph node-positive rectal cancer.

Seery TE, Ziogas A, Lin BS, Pan CJ, Stamos MJ, Zell JA.

J Gastrointest Surg. 2013 Feb;17(2):374-81. doi: 10.1007/s11605-012-2116-y. Epub 2012 Dec 14.

11.

Meat consumption, ornithine decarboxylase gene polymorphism, and outcomes after colorectal cancer diagnosis.

Zell JA, Lin BS, Ziogas A, Anton-Culver H.

J Carcinog. 2012;11:17. doi: 10.4103/1477-3163.104004. Epub 2012 Nov 28.

12.

Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer.

Rial NS, Zell JA, Cohen AM, Gerner EW.

Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):507-17. doi: 10.1586/egh.12.23. Review.

13.

Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas.

Zell JA, Lin BS, Madson N, McLaren CE, Gerner EW, Meyskens FL.

Cancer Causes Control. 2012 Oct;23(10):1739-44. doi: 10.1007/s10552-012-0051-6. Epub 2012 Aug 21.

14.

Population-based evaluation of adenosquamous carcinoma of the colon and rectum.

Masoomi H, Ziogas A, Lin BS, Barleben A, Mills S, Stamos MJ, Zell JA.

Dis Colon Rectum. 2012 May;55(5):509-14. doi: 10.1097/DCR.0b013e3182420953.

15.

Analysis of prognostic factors for patients with chordoma with use of the California Cancer Registry.

Lee J, Bhatia NN, Hoang BH, Ziogas A, Zell JA.

J Bone Joint Surg Am. 2012 Feb 15;94(4):356-63. doi: 10.2106/JBJS.J.01784.

PMID:
22336975
16.

Clinical trials update: Tertiary prevention of colorectal cancer.

Zell JA.

J Carcinog. 2011 Mar 24;10:8. doi: 10.4103/1477-3163.78271. No abstract available.

17.

Risk of second primary colorectal cancer among colorectal cancer cases: a population-based analysis.

Raj KP, Taylor TH, Wray C, Stamos MJ, Zell JA.

J Carcinog. 2011 Mar 17;10:6. doi: 10.4103/1477-3163.78114.

18.

Timing of radiation therapy, lymph node retrieval, and survival in rectal cancer.

Pan CJ, Ziogas A, Buchberg B, Raj KP, Mills SD, Stamos MJ, Zell JA.

Dis Colon Rectum. 2011 May;54(5):526-34. doi: 10.1007/DCR.0b013e31820939fb.

PMID:
21471752
19.

Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms.

Lipkin S, Lee J, Imagawa D, Hewitt SM, Tucker C, Zell JA, Wong V, Garcia A, Gonzalez R, Della Zanna G, Richmond E, Rodriguez LM, Bigg M, Schnoll-Sussmans F, Meyskens F.

Cancer Prev Res (Phila). 2011 Apr;4(4):512-3. doi: 10.1158/1940-6207.CAPR-10-0373.

20.

Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer.

Bessonova L, Taylor TH, Mehta RS, Zell JA, Anton-Culver H.

Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):389-96. doi: 10.1158/1055-9965.EPI-10-1016. Epub 2011 Jan 7.

21.

Adenosquamous versus adenocarcinoma of the pancreas: a population-based outcomes analysis.

Katz MH, Taylor TH, Al-Refaie WB, Hanna MH, Imagawa DK, Anton-Culver H, Zell JA.

J Gastrointest Surg. 2011 Jan;15(1):165-74. doi: 10.1007/s11605-010-1378-5. Epub 2010 Nov 17.

22.

Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.

Zell JA, McLaren CE, Chen WP, Thompson PA, Gerner EW, Meyskens FL.

J Natl Cancer Inst. 2010 Oct 6;102(19):1513-6. doi: 10.1093/jnci/djq325. Epub 2010 Aug 26.

23.
24.

Meat consumption, nonsteroidal anti-inflammatory drug use, and mortality among colorectal cancer patients in the California Teachers Study.

Zell JA, Ziogas A, Bernstein L, Clarke CA, Deapen D, Largent JA, Neuhausen SL, Stram DO, Ursin G, Anton-Culver H.

Cancer Prev Res (Phila). 2010 Jul;3(7):865-75. doi: 10.1158/1940-6207.CAPR-09-0262. Epub 2010 Jun 15.

25.

Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.

Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, Meyskens FL, Gerner EW.

Gastroenterology. 2010 Sep;139(3):797-805, 805.e1. doi: 10.1053/j.gastro.2010.06.005. Epub 2010 Jun 9.

26.

Hypertension, antihypertensive medication use, and breast cancer risk in the California Teachers Study cohort.

Largent JA, Bernstein L, Horn-Ross PL, Marshall SF, Neuhausen S, Reynolds P, Ursin G, Zell JA, Ziogas A, Anton-Culver H.

Cancer Causes Control. 2010 Oct;21(10):1615-24. doi: 10.1007/s10552-010-9590-x. Epub 2010 Jun 6.

28.

Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry.

Lee J, Hoang BH, Ziogas A, Zell JA.

Cancer. 2010 Apr 15;116(8):1964-73. doi: 10.1002/cncr.24937.

29.
30.
31.

Review of epidemiologic data on the debate over smokeless tobacco's role in harm reduction.

Timberlake DS, Zell JA.

BMC Med. 2009 Oct 19;7:61. doi: 10.1186/1741-7015-7-61. Review.

32.

Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis.

Zell JA, Ziogas A, Bernstein L, Clarke CA, Deapen D, Largent JA, Neuhausen SL, Stram DO, Ursin G, Anton-Culver H.

Cancer. 2009 Dec 15;115(24):5662-71. doi: 10.1002/cncr.24705.

33.

Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival.

Zell JA, Ziogas A, Ignatenko N, Honda J, Qu N, Bobbs AS, Neuhausen SL, Gerner EW, Anton-Culver H.

Clin Cancer Res. 2009 Oct 1;15(19):6208-16. doi: 10.1158/1078-0432.CCR-09-0592. Epub 2009 Sep 29.

34.

Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies.

Ou SH, Zell JA.

J Thorac Oncol. 2009 Oct;4(10):1202-11. doi: 10.1097/JTO.0b013e3181b28fb9.

35.
36.

Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis.

Wray CM, Ziogas A, Hinojosa MW, Le H, Stamos MJ, Zell JA.

Dis Colon Rectum. 2009 Aug;52(8):1359-66. doi: 10.1007/DCR.0b013e3181a7b7de.

PMID:
19617745
37.

Survival prognostication in non-small cell lung cancer.

Zell JA, Ignatius Ou SH.

J Thorac Oncol. 2009 Jul;4(7):785-6. doi: 10.1097/JTO.0b013e3181a99fa2. No abstract available.

38.

The effect of tumor size on non-size-based descriptors in staging of stage I non-small cell lung cancer.

Ou SI, Zell JA.

Chest. 2009 Jun;135(6):1695-1696. doi: 10.1378/chest.09-0406. No abstract available.

PMID:
19497911
39.

Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.

Zell JA, Pelot D, Chen WP, McLaren CE, Gerner EW, Meyskens FL.

Cancer Prev Res (Phila). 2009 Mar;2(3):209-12. doi: 10.1158/1940-6207.CAPR-08-0203. Epub 2009 Mar 3.

40.

Need for a new treatment strategy: leptomeningeal carcinomatosis from gastric cancer.

Raj KP, Sanati H, Mehta RS, Zell JA.

Anticancer Drugs. 2009 Apr;20(4):301-4. doi: 10.1097/CAD.0b013e328329707c.

PMID:
19247177
41.
42.
43.

Survival of distinct Asian groups among colorectal cancer cases in California.

Le H, Ziogas A, Taylor TH, Lipkin SM, Zell JA.

Cancer. 2009 Jan 15;115(2):259-70. doi: 10.1002/cncr.24034.

44.
45.

Survival after colorectal cancer diagnosis is associated with colorectal cancer family history.

Zell JA, Honda J, Ziogas A, Anton-Culver H.

Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3134-40. doi: 10.1158/1055-9965.EPI-08-0587.

46.

A population-based, descriptive analysis of malignant intraductal papillary mucinous neoplasms of the pancreas.

Le H, Ziogas A, Rhee JM, Lee JG, Lipkin SM, Zell JA.

Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2737-41. doi: 10.1158/1055-9965.EPI-08-0417.

47.

Effects of socioeconomic status and treatment disparities in colorectal cancer survival.

Le H, Ziogas A, Lipkin SM, Zell JA.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1950-62. doi: 10.1158/1055-9965.EPI-07-2774.

48.

Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer.

Ou SH, Zell JA.

J Thorac Oncol. 2008 Aug;3(8):880-6. doi: 10.1097/JTO.0b013e31817dfced.

49.

Identification of HDM2 as a regulator of VEGF expression in cancer cells.

Narasimhan M, Rose R, Ramakrishnan R, Zell JA, Rathinavelu A.

Life Sci. 2008 Jun 20;82(25-26):1231-41. doi: 10.1016/j.lfs.2008.04.004. Epub 2008 May 27.

PMID:
18504050
50.

Supplemental Content

Support Center